presents
Held on 13-14th November 2025
BELFAST, UK
Our exclusive interactive event designed to equip participants with essential skills and knowledge in investor-readiness, Target-Product Profiles, preclinical research, health economics, and intellectual property.
“You could have an incredible drug that works, but if payers won’t pay, it will never reach the patients who need it." - Prof. Chris McCabe
Retinnovate was born from this very mantra - educating and bridging the gap between scientific innovation and commercial success. This bootcamp brings together experts in preclinical modelLing, regulatory strategy, IP, health economics, and investment to give retinal disease innovators the tools to improve investor onboarding and increase success - not just in treating patients, but in navigating the different market payers.
Dr. James Bojdo
Programme Director, Retinnovate
Congrats to the 2025 pitch winners!
🏆 Congratulations to Re-Vana Therapeutics, awarded first prize at Retinnovate 2025!
The judges were impressed by OcuLief®, a biodegradable platform delivered as a liquid through a 25G needle that forms implants of up to 60mg 𝘪𝘯 𝘴𝘪𝘵𝘶 for sustained, controlled delivery of therapeutics to the posterior segment of the eye.
This innovative approach has the potential to:
🔹 reduce the need for frequent intravitreal injections
🔹 improve patient compliance
🔹 reduce treatment burden
🔹 support better long-term outcomes in chronic retinal disease
A fantastic achievement - congratulations again to the Re-Vana team 👏
🥈 Congratulations to Suil Pharmaceuticals and Cormac Flynn, awarded second prize at RetInnovate 2025!
Their technology aims to improve outcomes in diabetic macular edema by addressing variability in treatment response and improving efficacy in a patient group with significant unmet clinical need.
This award will help support the next stage of validation through targeted in vivo cystoid edema studies with MediNect Ophtho, strengthening the translational pathway for the technology.An exciting step forward for the team and a well-deserved recognition 👏
🥉 Congratulations to University College Dublin & South East Technological University, awarded third prize at RetInnovate 2025!
Their innovative eye drop formulations are designed to target both anterior and posterior segment eye diseases, addressing one of the key challenges in ophthalmology drug delivery: achieving effective penetration to the back of the eye through a non-invasive route.
A great example of the breadth and promise of innovation emerging in ophthalmology 👏
